|
|
Volumn , Issue , 2013, Pages 374-380
|
|
Limited-stage Hodgkin lymphoma: optimal chemotherapy and the role of radiotherapy
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALKYLATING AGENT;
ANTINEOPLASTIC AGENT;
BLEOMYCIN;
CYCLOPHOSPHAMIDE;
DACARBAZINE;
DOXORUBICIN;
ETOPOSIDE;
PREDNISONE;
PROCARBAZINE;
VINBLASTINE;
VINCRISTINE;
ADJUVANT THERAPY;
ADVERSE EFFECTS;
CANCER STAGING;
CLINICAL TRIAL (TOPIC);
COHORT ANALYSIS;
HODGKIN DISEASE;
HUMAN;
LEUKEMIA, RADIATION-INDUCED;
MULTIMODALITY CANCER THERAPY;
NEOPLASMS, SECOND PRIMARY;
PATHOLOGY;
PATIENT SELECTION;
POSITRON EMISSION TOMOGRAPHY;
PROCEDURES;
RADIATION DOSE;
RISK ASSESSMENT;
SCINTISCANNING;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS, ALKYLATING;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BLEOMYCIN;
CLINICAL TRIALS AS TOPIC;
COHORT STUDIES;
COMBINED MODALITY THERAPY;
CYCLOPHOSPHAMIDE;
DACARBAZINE;
DOXORUBICIN;
ETOPOSIDE;
HODGKIN DISEASE;
HUMANS;
LEUKEMIA, RADIATION-INDUCED;
NEOPLASM STAGING;
NEOPLASMS, SECOND PRIMARY;
PATIENT SELECTION;
POSITRON-EMISSION TOMOGRAPHY;
PREDNISONE;
PROCARBAZINE;
RADIOTHERAPY DOSAGE;
RADIOTHERAPY, ADJUVANT;
RISK ASSESSMENT;
TREATMENT OUTCOME;
VINBLASTINE;
VINCRISTINE;
|
|
EID: 84913556573
PISSN: None
EISSN: 15488756
Source Type: Journal
DOI: 10.1200/EdBook_AM.2013.33.374 Document Type: Review |
|
Times cited : (6)
|
|
References (0)
|